Pacific Biosciences, Inc. (PACB) , popularly known as PacBio, has signed a new Research Collaboration Agreement with the National Cancer Centre of Singapore (NCCS) to enhance Asian cancer research. Leveraging PacBio's Onso short-read sequencing platform, the collaboration aims to enable researchers to profile the genomic landscape of prevalent cancers, including gastrointestinal stromal tumors. PacBio's partner, Diethelm Keller Siber Hegner (DKSH), a Swiss company specializing in market expansion services, ...

SINGAPORE, Oct. 11, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the signing of a new Research Collaboration Agreement (RCA) with the National Cancer Centre of Singapore (NCCS). This collaboration aims to accelerate cancer research by leveraging PacBio's advanced sequencing technologies, including the innovative Onso short-read sequencing platform, to profile the genomic landscape of prevalent cancers in Asia. The ...

MENLO PARK, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2024 financial results on Thursday, November 7, 2024, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at https://investor.pacificbiosciences.com/. Date: Thursday, November 7, 2024, at 4:30 pm ET (1:30 pm PT) Listen live via internet or replay: https://investor.pacificbiosciences.com/ Toll-free: 1-888 ...

The most recent trading session ended with Pacific Biosciences of California (PACB) standing at $1.81, reflecting a +0.56% shift from the previouse trading day's closing. The stock outperformed the S&P 500, which registered a daily gain of 0.54%. At the same time, the Dow added 0.72%, and the tech-heavy Nasdaq gained 0.65%. Prior to today's trading, shares of the maker of genetic analysis technology had gained 6.51% over the past month. This has outpaced the Medical sector's gain of 4.37% and the S&P 500's ...

Pacific Biosciences of California, Inc. (PACB) or PacBio recently announced a collaboration with HiFi Solves Sub-Fertility Consortium, led by KK Women's and Children's Hospital in Singapore. The consortium will use PACB's HiFi long-read sequencing to pioneer advancements in diagnosing and treating subfertility and recurrent pregnancy loss (RPL). The consortium includes experts from five leading centers across the AsiaPacific region and leverages DNAstack's federated data platform to ensure secure, global co ...

Pacific Biosciences of California, Inc. (PACB) has announced a collaboration with the University Hospital of Munster to use its Revio HiFi sequencing system in advancing research on male infertility and rare diseases. Munster is pioneering long-read whole genome sequencing in Germany, integrating it into research and diagnostics. This initiative will explore complex genetic issues, including the Y chromosome's role in male infertility, and support Germany's GenomeDE Modellvorhaben project. The results will ...

SINGAPORE, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The HiFi Solves Sub-fertility Consortium, an innovative collaboration involving five leading centers across the Asia-Pacific region, announces work aimed at redefining the landscape of fertility research. Utilizing PacBio HiFi long-read sequencing, the consortium, led by KK Women's and Children's Hospital (KKH) in Singapore, is pioneering the use of PacBio HiFi long-read sequencing to enhance the diagnosis and treatment of subfertility and recurrent miscarriages ...

MENLO PARK, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a collaboration with the University Hospital of Münster, to use long-read whole genome sequencing to significantly advance male infertility and rare disease research. By deploying PacBio's Revio HiFi sequencing system, researchers at Münster will obtain highly accurate genomic data essential for addressing complex genetic issues associated w ...

Mongkol Onnuan Pacific Biosciences: Sustained Weakness in Genomic Sequencing Market Pacific Biosciences of California's (NASDAQ:PACB) stock is down 20% since my "sell" recommendation in June following its Q1 earnings report. I expressed concerns regarding Pacific's "high SG&A costs (relative to revenues), declining product revenues, and low gross margins" amidst a competitive genomic sequencing market. The company reported Q2 earnings on August 7. Unfortunately, the results continue to highlight the signifi ...

alanphillips/E+ via Getty Images The performance of Pacific Biosciences (NASDAQ:PACB) ("PacBio") is all too familiar to readers who've followed this stock for a long time, as once again the stock is trading below $2 on fears that the company simply won't be able to stay in the game long enough to benefit from future growth in long-read sequencing (as well as skepticism that long-read sequencing will grow enough to support a $1B+ revenue base). Down more than 80% since my last update, underperforming other s ...